Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Adrian Wu who wrote (2517)	3/9/1999 2:51:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 4676

INTERVIEW-Isis to seek patents vs 100 genes in '99 biz.yahoo.com Very positive, especially these excerpts IMSCO Looks like some puzzling items are cleared up to (why the extra $$s, timing of Chrons...) Just in time after the downgrade. Wonder if the analyst regrets the move now? ;) Scott <<Crooke said Isis was eagerly awaiting final Phase III data, expected by late 1999, for the company's drug Isis 2302 against Crohn's disease, an inflammatory bowel condition for which there are now few good therapies. ''Assuming the data are positive, we expect to file the new drug application (NDA) at the latest by the first quarter of next year'' for the Crohn's disease indication, Crooke said. Isis has about $60 million in cash, Crooke added, with which it hopes to bring additional drugs to Phase I clinical trials by next year. He said the compounds include antisense agents against hepatitis C, and another compound that could be targeted against diabetes as well as against several types of inflammatory diseases. In addition, Crooke said that if finances allow, Isis would like to begin Phase I trials in early 2000 for an aerosol form of Isis 2302 against asthma and/or a Phase I trial of a topical form of the drug against psoriasis.>>